Weekly adalimumab most cost-efficient for HS in 5 countries

Editor's Pick: Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa (JAMA Dermatology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease classification and the economics of biologics, real-world outcomes in atopic dermatitis and psoriasis, and a cluster of practical papers on infection, hair loss, and melanocytic lesion surveillance. Let's dive in.

This week's papers:

1. Pyoderma Gangrenosum Phenotype Classification. JAMA Dermatology 2026
2. Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa. JAMA Dermatology 2026
3. Treatment of tinea capitis in China: a multicenter prospective real-world study. Journal of the American Academy of Dermatology 2026
4. Risk-adapted monitoring of melanocytic lesions with peripheral globules: a longitudinal cohort study on melanoma risk stratification. Journal of the American Academy of Dermatology 2026
5. Systemic Comorbidities in Central Centrifugal Cicatricial Alopecia: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica 2026
6. Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast. Dermatology 2026
7. Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study. Clinical and Experimental Dermatology 2026
8. Staphylococcal Scalded Skin Syndrome Often Does Not Require Empiric Coverage for Methicillin Resistance. Pediatric Dermatology 2026
9. Early Clinical Response Predicts Treatment Persistence in Advanced Therapy-naive Atopic Dermatitis. Acta Dermato-Venereologica 2026
10. Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry. Acta Dermato-Venereologica 2026

Listen at AudioScholar